Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To investigate the comparative effectiveness of trastuzumab emtansine (T-DM1) in a real-world population of HER2+ metastatic breast cancer (mBC) patients. Materials & methods: The Flatiron Health database was used to identify a cohort of HER2+ mBC patients who received first-line trastuzumab treatment and T-DM1 or lapatinib plus chemotherapy as second-line treatment. Overall survival was compared between the two groups. Results: A total of 278 patients with HER2+ mBC received second-line T-DM1 and 34 lapatinib plus chemotherapy. Overall survival was longer in patients treated with T-DM1 than those treated with lapatinib plus chemotherapy (adjusted hazard ratio: 0.56; 95% CI: 0.38–0.85). Conclusion: Real-world data supports the effectiveness of T-DM1 in the second-line treatment of HER2+ mBC patients.
Lay abstract
EMILIA was a randomized clinical trial (RCT) – a type of study designed to test whether a treatment works in a particular disease, using methods to remove possible bias. The study showed that a treatment called trastuzumab emtansine (shortened to T-DM1) improved the survival of patients with a particular type of breast cancer, known as HER2+ metastatic breast cancer (mBC). However, as clinical trials are run under controlled conditions, they do not fully reflect results under normal circumstances. In this study, we looked at the effect of treating a ‘real’ population of HER2+ mBC patients with T-DM1 in the USA. We found that T-DM1 still improved survival in these ‘real-world’ patients. Studies in the ‘real world’ can have some bias, as they are not controlled like RCTs; however, taking the results of the EMILIA RCT, along with the results of our study, supports the use of T-DM1 as a treatment option for HER2+ mBC patients.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: •• of considerable interest
1.
Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783–1791 (2012).
2.
Diéras V, Miles D, Verma S et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, Phase III trial. Lancet Oncol. 18(6), 732–742 (2017).
•• Final overall results of the EMILIA trial.
3.
Khozin S, Miksad RA, Adami J et al. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer. Cancer 125(22), 4019–4032 (2019).
4.
Conte B, Fabi A, Poggio F et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin. Breast Cancer 20(2), e181–e187 (2020).
5.
Vici P, Pizzuti L, Michelotti A et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget 8(34), 56921–56931 (2017).
6.
Dzimitrowicz H, Berger M, Vargo C et al. T-DM1 activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab and pertuzumab. J. Clin. Oncol. 34(29), 3511–3517 (2016).
7.
Noda-Narita S, Shimomura A, Kawachi A et al. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Breast Cancer 26(4), 492–498 (2019).
8.
Gong IY, Yan AT, Earle CC, Trudeau ME, Eisen A, Chan KKW. Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes. Breast Cancer Res. Treat. 181(1), 155–165 (2020).
9.
Lupichuk S, Cheung WY, Stewart D. Pertuzumab and trastuzumab emtansine for human epidermal growth factor receptor-2-positive metastatic breast cancer: contemporary population-based outcomes. Breast Cancer 13, (.2019) (Epub ahead of print).
10.
McDonald L, Schultze A, Carroll R, Ramagopalan SV. Performing studies using the UK Clinical Practice Research Datalink: to link or not to link? Eur. J. Epidemiol. 33(6), 601–605 (2018).
Information & Authors
Information
Published In
Pages: 595 - 602
PubMed: 33095031
Copyright
© 2021 Ramagopalan et al. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 15 September 2020
Accepted: 22 February 2021
Published online: 31 March 2021
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2020-0201
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Ippokratis Korantzis, Anna Koumarianou, Vassiliki Rapti, Eleni Timotheadou, Christos Christodoulou, Dimitrios Tryfonopoulos, Sofia Karageorgopoulou, Ioannis Boukovinas, Flora Zagouri, Adamantia Nikolaidi, Konstantinos Papazisis, Evangelia Razis, Vasileios Barbounis, Athina Christopoulou, Dimitrios Mavroudis, Vassilios Georgoulias, Georgios Kesisis, Emmanuel I. Papadopoulos, Rozalia Michalea, Alexandros Ardavanis, Real-world management strategies and clinical outcomes of metastatic HER2-positive breast cancer in Greece in the second-line setting and beyond (the togetHER study), BMC Cancer, 10.1186/s12885-025-14791-9, 25, 1, (2025).
- Ignacio Leiva-Escobar, Camilo Scherkl, Walter E Haefeli, Andreas D Meid, Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines, BMJ Open, 10.1136/bmjopen-2024-089218, 15, 7, (e089218), (2025).
- H. Jourdain, I. Mansouri, A. Di Meglio, M. Zureik, N. Haddy, Utilization and safety of trastuzumab emtansine (T-DM1): a nationwide population-based study using the French National Health Data System, ESMO Real World Data and Digital Oncology, 10.1016/j.esmorw.2024.100045, 4, (100045), (2024).
- Karen Gambaro, Mélanie Groleau, Suzan McNamara, Arif Awan, Maged Salem, Mahmoud Abdelsalam, Eve St-Hilaire, François Vincent, Julie Carrier, Helen MacKay, Louise Provencher, Dominique Boudreau, Zineb Hamilou, Fred Saad, Cristiano Ferrario, Gerald Batist, Maud Marques, Third-line treatment patterns in HER2-positive metastatic breast cancer: a retrospective analysis of real-world data in Canada, Journal of Pharmacy & Pharmaceutical Sciences, 10.3389/jpps.2023.12078, 26, (2023).
- Sandhya Mehta, Jipan Xie, Raluca Ionescu-Ittu, Xiaoyu Nie, Winghan J. Kwong, Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer, Oncology and Therapy, 10.1007/s40487-023-00241-8, 11, 4, (481-493), (2023).
- Carsten Bokemeyer, Noman Paracha, Ulrik Lassen, Antoine Italiano, Sean D. Sullivan, Marisca Marian, Nicoletta Brega, Jesus Garcia-Foncillas, Survival Outcomes of Patients With Tropomyosin Receptor Kinase Fusion-Positive Cancer Receiving Larotrectinib Versus Standard of Care: A Matching-Adjusted Indirect Comparison Using Real-World Data, JCO Precision Oncology, 10.1200/PO.22.00436, 7, (2023).
- Narmeen S. Rashid, Jacqueline M. Grible, Charles V. Clevenger, J. Chuck Harrell, Breast cancer liver metastasis: current and future treatment approaches, Clinical & Experimental Metastasis, 10.1007/s10585-021-10080-4, 38, 3, (263-277), (2021).